Trial Profile
Phase I trial of NDC 1308 for the treatment of multiple sclerosis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2016
Price :
$35
*
At a glance
- Drugs NDC 1308 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- 18 Apr 2016 The company expects to complete IND-enabling studies, file an IND application and initiate phase I human studies, according to an ENDECE media release.
- 17 Mar 2014 New trial record